Articles related to GENETIC TESTING/MUTATIONS

In the realm of rare diseases, early diagnosis is a critical challenge. Machine learning is emerging as a pivotal tool in identifying familial amyloid polyneuropathy (FAP) patients, promising a new era of precision in genetic testing and timely treatment initiation.

Explore the potential of CARv3-TEAM-E T cells in recurrent glioblastoma, a novel therapy showing promise with rapid tumor regression and no severe adverse effects in early clinical evaluation.

Explore the latest advancement in NSCLC treatment: the FDA-approved amivantamab combo has demonstrated a significant leap in progression-free survival for patients with specific genetic mutations, reshaping the standard of care.

The newly developed Real-CSF test offers a significant leap in diagnosing brain tumors, accurately identifying cancerous lesions in 67% of cases by analyzing cerebrospinal fluid for abnormal genetic material.

A look into the complexities of managing advanced melanoma with BRAF–MEK inhibitors, highlighting a case study where treatment-induced toxic effects posed significant diagnostic and therapeutic challenges.

In the CodeBreaK 100 study, a lower 240 mg dose of sotorasib demonstrated similar efficacy to the FDA-approved 960 mg dose in treating KRAS G12C–mutated NSCLC, with potentially fewer severe adverse events.